Next Article in Journal
TAK1 Mediates ROS Generation Triggered by the Specific Cephalosporins through Noncanonical Mechanisms
Previous Article in Journal
P27 Protects Neurons from Ischemic Damage by Suppressing Oxidative Stress and Increasing Autophagy in the Hippocampus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 24
10.3390/ijms21249498
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Prognostic Significance of COX-2 Overexpression in BRAF-Mutated Middle Eastern Papillary Thyroid Carcinoma

Int. J. Mol. Sci. 2020, 21(24), 9498; https://doi.org/10.3390/ijms21249498
by Sandeep Kumar Parvathareddy 1,†, Abdul K. Siraj 1,†, Padmanaban Annaiyappanaidu 1, Saif S. Al-Sobhi 2, Fouad Al-Dayel 3 and Khawla S. Al-Kuraya 1,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(24), 9498; https://doi.org/10.3390/ijms21249498
Submission received: 8 November 2020 / Revised: 27 November 2020 / Accepted: 10 December 2020 / Published: 14 December 2020
(This article belongs to the Section Molecular Oncology)

Round 1

Reviewer 1 Report

This is an interesting study to demonstrate the significance of COX-2 overexpression in BRAF mutated PTC. The study was well designed and performed in a systematic way.

 

However, some suggestions to improve this manuscript are:

  1. A schematic diagram can be included to summarize the findings and include future directions.
  2. Introduction section is too short, can be expanded.
  3. Conclusion section should be elaborated.
  4. Figure 2 seems to be blurred, can improve the resolution/quality of image.

Author Response

This is an interesting study to demonstrate the significance of COX-2 overexpression in BRAF mutated PTC. The study was well designed and performed in a systematic way.

We thank the reviewer for taking the time to review our manuscript and providing constructive feedback to improve the manuscript. It gives us immense pleasure to know that the reviewer finds our study to be “well designed and performed in a systematic way”. The concerns of the reviewer are addressed point by point below.

 

However, some suggestions to improve this manuscript are:

  1. A schematic diagram can be included to summarize the findings and include future directions.

We thank the reviewer for their valuable suggestion. As suggested by the reviewer, we have now included a schematic diagram to summarize the findings and future directions. This has been incorporated in the manuscript as Fig. 3 (Page 8, Line 176).

 

  1. Introduction section is too short, can be expanded.

We appreciate the reviewer’s concern regarding the Introduction section being too short. Respecting the reviewer’s suggestion, we have now expanded the Introduction. These changes are reflected in the manuscript (Page 2, Line 62-88).

 

  1. Conclusion section should be elaborated.

We thank the reviewer for their suggestion to elaborate the Conclusion section. As suggested by the reviewer, we have now expanded the Conclusion section in the manuscript (Page 9, Line 232-239).

 

  1. Figure 2 seems to be blurred, can improve the resolution/quality of image.

We appreciate the reviewer’s concern regarding the resolution/quality of the image in Figure 2. We would like to assure the reviewer that the current image is at 600 dpi resolution in accordance with the journal guidelines. The image probably only appears blurred in the pdf version.

 

Author Response File: Author Response.docx

Reviewer 2 Report

BRAF V600E is primarily present in conventional papillary thyroid cancer. It is associated with an aggressive tumor phenotype and higher risk of recurrent and persistent disease in patients with conventional papillary thyroid cancer.

It would be interesting to Know if any mutations other than BRAF V600E have been detected in your patient cohort.

Author Response

We thank the reviewer for taking the time to review our manuscript and providing constructive feedback to improve the manuscript. The concerns of the reviewer are addressed point by point below.

 

BRAF V600E is primarily present in conventional papillary thyroid cancer. It is associated with an aggressive tumor phenotype and higher risk of recurrent and persistent disease in patients with conventional papillary thyroid cancer.

It would be interesting to know if any mutations other than BRAFV600E have been detected in your patient cohort.

We acknowledge the reviewer’s interest in knowing if any mutations other than BRAFV600E have been detected in our patient cohort. In this cohort of 1335 PTC patients, NRAS mutation data was available for 1329 cases, with mutation noted in 6.4% (85/1329) of cases, whereas HRAS mutation data was available for 1328 cases, with mutation seen in 2.3% (30/1328) of cases. BRAF and RAS mutations were mutually exclusive, except for four cases (two cases had co-existing BRAF and NRAS mutations; two cases had co-existing BRAF and HRAS mutations). We have now added the data for NRAS and HRAS mutations in Table 1 (Page 3, Line 96) as well as in Methods section (Page 9, Line 193-194).

 

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The manuscript has been modified appropriately and has incorporated the comments and suggestions.

Back to TopTop